IL5 and Nasal polyposis: Anti-IL5- and anti-IL-5R biologics such as benralizumab and TPI ASM8 [63] have not been used in nasal polyposis, but a DBPC phase 3 study to evaluate benralizumab in patients with CRSwNP is currently being completed (OSTRO study) [64].